Big Pharma have made it clear they’re on the hunt for M&AFebruary 15, 2022 - [fiercebiotech.com] ...biopharma M&A expected to be a 'difference animal' in 2022
"Biopharmas have $1.7 Trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions. "
"After a slump in 2021, biopharma M&A is slated to pick up this year with an “innovation deficit” spurring shopping for new assets. Billions of dollars are obviously available for megadeals, and an endless sea of biotechs are giving shoppers a long list of options."
"Record-high waves of venture capital investment have flooded the drug development industry, which translates to expectations for deal valuations of $5 billion to $50 billion this year because of the sheer number of biotechs available for purchase, the PwC leader said."
https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t